

Hidradenitis Suppurativa

Understanding its epidemiology, pathophysiology, and clinical presentation



Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic inflammatory skin disorder^{1,2}

Manifests as painful lesions, abscesses, and scars



Primarily in intertriginous areas (axillary, groin, perianal, and perineal regions)

Prevalence and epidemiology of HS

Global estimates²



0.03% to 4.0%

In Australia²



0.67%

HS is more common among:



Women



Young people



People with obesity



Individuals who smoke



People with low annual income

Risk factors of HS¹

Genetic



33% to 40% have an affected first-degree relative



Associated with mutations in γ -secretase complex, *DCD*, *PSTP1P1*, *SOX9*, and *KLF5*

Environmental



Medication



Cutaneous microbiome dysregulation



Mechanical friction

Behavioural



Smoking

Additional triggers



Hormonal changes during menstruation and menopause



Stress



Excessive heat and perspiration



Weight gain

Clinical presentation of HS¹

Symptoms preceding lesions

- Burning, pain, pruritus, warmth, and hyperhidrosis

Lesions

- Deep-seated nodules 0.5 to 2 cm (persisting for days to months)
- May have serosanguinous discharge
- Recurrent nodules, prone to rupture
- Tunnels and tracts that may ulcerate

Clinical classification of HS¹

Hurley stage I

- Abscesses lack tunnels and scars

Hurley stage II


- Recurrent abscesses with tunnels and scars
- Single or multiple lesions widely separated

Hurley stage III

- Diffusely involves the skin
- Lesions with multiple interconnected sinus tracts
- Abscesses occupy large areas

HS-associated comorbidities^{1,3*}

*Percentages in Australian patients³



Impact on quality of life^{1,4}

Physical discomfort



Pain



Drainage



Malodour



Bleeding



Scarring



Difficulty moving limbs

Psychosocial impact



Depression



Social isolation (embarrassment and self-consciousness)



Employment difficulties



Sexual dysfunction



Higher rate of suicide

Proper disease management and psychosocial support are essential for improving the quality of life of patients with late-stage HS⁴

The exact causes and pathogenic mechanisms underlying HS development and progression are only partially understood⁵

Early HS⁶



- Infiltration of neutrophils, innate immune cells, and lymphocytes
- Follicular hyperkeratosis and plugging
- Sebum accumulation and secretion
- Keratin debris causing folliculitis
- Bacterial dysbiosis

Advanced HS^{1,6}



- Rupture of inflamed follicles
- Advanced perifolliculitis
- Dermal inflammation
- Infiltration of immune cells

Chronic, uncontrolled inflammation driven by⁵:



- Innate immune cytokines
- B cells
- Neutrophil extracellular traps
- Complement activation
- Damaging autoantibodies

- Abscess formation
- Dermal tunnels with discharge
- Tissue destruction and scarring

HS diagnosis¹

Clinical diagnostic criteria^{1,2}



Types of lesions

Characteristic nodules, abscesses, tunnels, and scars



Location

Intertriginous areas



Chronicity

Histopathological features of HS include¹:

- Follicular occlusion
- Follicular hyperkeratosis
- Infundibular follicular epithelial hyperplasia
- Epidermal psoriasiform hyperplasia



- Keratin plugging
- Perifolliculitis (predominantly lymphocytic)
- Plasmacytic infiltrate
- Pseudoepitheliomatous hyperplasia

Differential diagnosis of HS¹



Conditions to be ruled out

- Follicular pyoderma (including folliculitis, furuncles, and carbuncles)
- Granuloma inguinale
- Nodulo-ulcerative syphilis
- Tuberculous abscess
- Actinomycosis
- Lymphogranuloma venereum
- Acne vulgaris
- Epidermoid, dermoid, pilonidal, or Bartholin's cysts
- Crohn's disease (particularly, with perianal involvement)



Conditions to be included

- Granulomatous diseases (Crohn's disease, sarcoidosis, mycobacterial infection)
- Chronic deep folliculitis
- Langerhans cell histiocytosis
- Folliculotropic mycosis fungoides
- Pyoderma gangrenosum
- Follicular rupture
- Abscess

Multiple other conditions with similar histopathology, including squamous cell carcinoma, need to be ruled out through biopsy during the HS diagnosis¹


Challenges to HS diagnosis



Symptom onset →



HS diagnosis: 7.23 ± 2.81 years^{2,7}



In Australia, diagnosis rates are low²

Reasons for delayed diagnosis^{2,7}

- Challenges to correctly diagnose HS at early stages
- Decentralisation of care
- Clinicians' unfamiliarity with the disease
- Misdiagnosis by clinicians
- Patients delaying seeking medical care
- Poor access to dermatology care


Blood, microbiological, histological, and imaging analyses using ultrasonography and magnetic resonance imaging may help in the accurate and early diagnosis of HS

Interdisciplinary management of HS¹



Treatment

- Antibiotics (topical, oral, and intravenous)
- Anti-inflammatory medications
- Antiandrogen agents
- Metformin
- Pain management



Biologic therapy

- Anti-TNF- α antibody (adalimumab)
- IL-17 inhibitors (secukinumab and bimekizumab)



Surgical therapy

- Laser therapy
- Punch debridement
- Deroofing
- Excision with skin grafting



Lifestyle modifications

- Maintaining a healthy weight
- Smoking cessation
- Avoiding tight clothing, harsh cleansers, and adhesive dressings



Psychosocial support

- Patient education, counselling, and support
- Important to reassure patients that the condition is non-contagious and not caused by poor hygiene

TNF: Tumour necrosis factor; IL: Interleukin

Key messages

- Increased awareness of the differential diagnosis of HS is necessary among the medical community to improve diagnosis, reduce delays in diagnosis, and provide timely treatment
- Chronic relapsing inflammation is the main pathogenic mechanism driving HS progression and an improved understanding of the complex interactions can help identify potential therapeutic targets
- Interdisciplinary management and support for the psychosocial aspects of HS are needed to improve the physical functioning and emotional well-being of patients with HS

References

- Ballard, K., & Shuman, V. L. (2024). Hidradenitis Suppurativa. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing 2025. <https://www.ncbi.nlm.nih.gov/books/NBK534867/>
- Calao, M., Wilson, J. L., Spelman, L., Billot, L., Rubel, D., Watts, A. D., & Jemec, G. B. E. (2018). Hidradenitis suppurativa (HS) prevalence, demographics and management pathways in Australia: A population-based cross-sectional study. *PLoS ONE*, *13*(7), e0200683.
- Vekic, D. A., & Cains, G. D. (2017). Hidradenitis suppurativa - Management, comorbidities and monitoring. *Australian Family Physician*, *46*(8), 584-588.
- McKenzie, S. A., Harvieu, C. L., Truong, A. K., Grogan, T. R., Shi, V. Y., Bennett, R. G., & Hsiao, J. L. (2020). Physical symptoms and psychosocial problems associated with hidradenitis suppurativa: correlation with Hurley stage. *Dermatology Online Journal*, *26*(9).
- Frew, J. W. (2025). Unravelling the complex pathogenesis of hidradenitis suppurativa. *British Journal of Dermatology*, *192*(Supplement_1), i3-i14.
- Krueger, J. G., Frew, J., Jemec, G. B. E., Kimball, A. B., Kirby, B., Bechara, F. G., Navrazhina, K., Prens, E., Reich, K., Cullen, E., & Wolk, K. (2024). Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape. *British Journal of Dermatology*, *190*(2), 149-162.
- Tsentemidou, A., Vakirlis, E., Bakirtzi, K., Chatzi-Sotiriou, T., Lallas, A., Kiritsi, D., & Sotiriou, E. (2024). Diagnostic delay in hidradenitis suppurativa: a systematic review and novel data from a Greek cohort. *Australasian Journal of Dermatology*, *65*(4), 378-380.

